| Type: |
Conjugated Primary Antibody |
| Conjugated with: |
594, ALEXA FLUOR® |
| Host organism: |
Goat (Capra aegagrus hircus) |
| Target Protein/Peptide: |
Complement C3 |
| Specificity: |
This antibody reacts specifically with Complement C3 |
| Modification: |
No modification has been applied to this antibody |
| Modification site: |
None |
| Clonality: |
Polyclonal Antibody |
| Clone: |
Polyclonal Antibodies |
| Concentration: |
1ug per 1ul |
| Antigen Source: |
human Complement C3 purified from human plasma |
| Gene ID: |
718 |
| Applications: |
IF(IHC-P) |
| Applications with corresponding dilutions: |
IF(IHC-P)(1:50-200) |
| Cross reactive species: |
Human (Homo sapiens) |
| Cross Reactive Species details: |
However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species, No significant cross reactivity has been observed for this antibody for the tested species |
| Background information: |
C3 is a central factor in the complement cascade, C3 is an acute phase protein that is produced by a wide range of tissues, C3g and C3c, Further degradation leads to the formation of the alpha chain products C3d, It is central to the alternative pathway that leads to the C3 convertase C3bBb, The classical mannose binding lectin activation pathway leads to the C3 convertase C4b2a, These convertases cleave C3 resulting in C3a and C3b, including renal epithelial cells and hepatocytes, The complement factor C3 consists of an alpha and a beta chain |
| Purification method: |
Purified by Protein A |
| Storage: |
50% glycerol and 0, Store at 4°, 09% sodium azide, C for 12 months, Water buffered solution containing 100ug/ml BSA |
| Excitation emission: |
590nm/617nm |
| Synonyms: |
CPAMD1 ARMD9 C3a C3b |
| Also known as: |
Complement C3 Polyclonal Antibody |
| Other name: |
Anti-Complement C3 Polyclonal |
| Advisory: |
For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube, Prior to use briefly centrifuge the vial to gather all the solution on the bottom, specificity and sensitivity, thus reducing its reactivity, Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody |
| Properties: |
For facs or microscopy Alexa 1 conjugate |
| Conjugation: |
Alexa Fluor |
| Group: |
Polyclonals and antibodies |
| About: |
The advantage is that there are more epitopes available in a polyclonal antiserum to detect the proteins than in monoclonal sera, immunohistochemistry on frozen slices or parrafin fixed tissues, Polyclonals can be used for Western blot |
| Gene target: |
Complement C3 |
| Short name: |
Anti-Complement C3 (Polyclonal) Fluor 594 |
| Technique: |
Pabs are a collection of immunoglobulin , Polyclonal antibodies , each identifying a different , whereas , (pAbs) are mostly rabbit or goat , B cells, Polyclonal, antibodies , antigen, come from a single N cell lineage, epitope, molecules that react against a specific , monoclonal antibodies , that are secreted by different |
| Label: |
ALEXA |
| Alternative name: |
ALEXA Fluor 594, antibody to-Complement complement component 3 (polyclonal) |
| Alternative technique: |
polyclonals |
| Alternative to gene target: |
AHUS5 and ARMD9 and ASP and C3a and C3b and CPAMD1 and HEL-S-62p, BT, C3 and IDBG-193788 and ENSMUSG00000024164 and 102642251, C3 and IDBG-21798 and ENSG00000125730 and 718, C5L2 anaphylatoxin chemotactic receptor binding, Extracellular, alternative pathway and biological process this GO :0006958 and complement activation, classical pathway and biological process this GO :0007165 and signal transduction and biological process this GO :0007186 and G-protein coupled receptor signaling pathway and biological process this GO :0010575 and positive regulation vascular endothelial growth factor production and biological process this GO :0010828 and positive regulation of glucose transport and biological process this GO :0010866 and regulation of triglyceride biosynthetic process and biological process this GO :0010884 and positive regulation of lipid storage and biological process this GO :0010951 and negative regulation of endopeptidase activity and biological process this GO :0030449 and regulation of complement activation and biological process this GO :0031715 and C5L2 anaphylatoxin chemotactic receptor binding and molecular function this GO :0045087 and innate immune response and biological process this GO :0045745 and positive regulation of G-protein coupled receptor protein signaling pathway and biological process this GO :0045766 and positive regulation of angiogenesis and biological process this GO :0050766 and positive regulation of pha this GO cytosis and biological process this GO :0050776 and regulation of immune response and biological process this GO :0070062 and extracellular vesicular exosome and cellular component this GO :0072562 and blood microparticle and cellular component this GO :2000427 and positive regulation of apoptotic cell clearance and biological process, this GO :0001798 and positive regulation of type IIa hypersensitivity and biological process this GO :0001934 and positive regulation of protein phosphorylation and biological process this GO :0001970 and positive regulation of activation of membrane attack complex and biological process this GO :0004866 and endopeptidase inhibitor activity and molecular function this GO :0005102 and receptor binding and molecular function this GO :0005515 and protein binding and molecular function this GO :0005576 and extracellular region and cellular component this GO :0005615 and extracellular space and cellular component this GO :0005886 and plasma membrane and cellular component this GO :0006631 and fatty acid metabolic process and biological process this GO :0006954 and inflammatory response and biological process this GO :0006955 and immune response and biological process this GO :0006956 and complement activation and biological process this GO :0006957 and complement activation, this GO :0004866 : endopeptidase inhibitor activity, this GO :0004866 : endopeptidase inhibitor activity and also this GO :0005102 : receptor binding and also this GO :0005515 : protein binding and also this GO :0031715 : C5L2 anaphylatoxin chemotactic receptor binding, this GO :0005102 : receptor binding, this GO :0005515 : protein binding, this GO :0031715 : C5L2 anaphylatoxin chemotactic receptor binding, 12266, 19562 and IDBG-643930 and ENSBTAG00000017280 and 280677, complement component 3 |
| Identity: |
1318 |
| Gene: |
C3 |
More about : C3 |
| Long gene name: |
complement C3 |
| Synonyms gene name: |
complement component 3 |
| Synonyms name: |
C3a anaphylatoxin complement component C3a complement component C3b prepro-C3 |
| Locus: |
19p13, 3 |
| Discovery year: |
2001-06-22 |
| GenBank acession: |
J04763 |
| Entrez gene record: |
718 |
| RefSeq identity: |
NM_000064 |
| Classification: |
Endogenous ligands Complement system C3 and PZP like, alpha-2-macroglobulin domain containing |
| Havana BLAST/BLAT: |
OTTHUMG00000150335 |
| Locus Specific Databases: |
C3base: Mutation registry for C3 deficiency LRG_27 |